Metropolitan Life Insurance Company (MetLife)’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PAND Stock Details PAND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,702	Closed	-$222K	–	2961
2021 Q1	$222K	Buy	+3,702	New	+$134K	﹤0.01%	1944

Metropolitan Life Insurance Company (MetLife)'s PAND Position: Q2 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 3,702 shares — an estimated $222K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PAND in Q1 2021 and held it in 1 quarter. The position peaked at $222K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 3,702 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $222K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Pandion Therapeutics Inc. Common Stock in Q1 2021 and held it in 1 quarter.
Metropolitan Life Insurance Company (MetLife)'s Pandion Therapeutics Inc. Common Stock position peaked at $222K in Q1 2021.
0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2021, filed 16 Aug 2021.